Medical cannabis in Europe 2026: which countries allow it, for which diseases and how to access it

There is enormous confusion between the debate on cannabis legalisation and access to medical cannabis. They are two distinct conversations. While countries like Germany make press headlines about the end of the recreational prohibition, thousands of European patients with refractory epilepsy, multiple sclerosis or neuropathic pain still don't have clear access to the treatments they need.

This article documents, with verified data from official regulatory agencies, what really exists in Europe in 2026: which medicines are approved, in which countries, for which diseases exactly, and how a patient can access them — including what happens when travelling abroad with their medication.

No myths. No theories. Only what the EMA, AEMPS, BfArM and the official bulletins of each country say.

Medical cannabis vs. recreational cannabis: the difference that matters

Medical cannabis is not "smoking marijuana with a prescription". These are medicines manufactured under pharmaceutical standards — GMP (Good Manufacturing Practices) — with exact cannabinoid concentrations, controlled dosage and authorisation procedures identical to any other drug.

The EMA (European Medicines Agency) evaluates and authorises these medicines just as it would evaluate an antibiotic or a cancer drug. A doctor prescribes them for specific clinical indications, just like any other treatment. A pharmacy — generally a hospital pharmacy — dispenses them.

What changes between countries is not "whether cannabis is allowed", but which of these medicines have marketing authorisation, whether the national health system funds them, and what type of doctor can prescribe them. In some countries, that gap between what the law says and what a real patient can do is enormous.

Cannabis medicines with official approval in Europe

Before talking about countries, it is essential to understand what products exist. There are only two cannabis-derived medicines with centralised authorisation from the EMA, valid in all 27 EU states plus Norway, Iceland and Liechtenstein.

Other cannabinoids: nabilone and dronabinol

Nabilone (Cesamet/Canemes) is a synthetic cannabinoid — not plant-derived — indicated for nausea and vomiting from refractory chemotherapy. It has national authorisations in Austria, Germany, Ireland and the United Kingdom, but not in most EU countries.

Dronabinol (synthetic THC) has no finished product with EMA authorisation or standard national approval in most EU states. In Germany, it can be prescribed as a compounded preparation in pharmacies or imported from the US under special procedures.

Map of medical cannabis in Europe 2026: country by country

Other countries: summary table

For which diseases is medical cannabis approved

This is the most misunderstood part. Just because medical cannabis is "legal" in a country does not mean a doctor can prescribe it for any ailment. Regulatory authorisation is indication-specific.

Indications with official authorisation in Europe

Off-label uses: what doctors can do (with nuances)

In countries with broad frameworks — Germany, Netherlands, UK, Czech Republic — doctors can prescribe medical cannabis outside authorised indications (off-label) based on their clinical judgement. This occurs in practice for conditions such as:

• Chronic neuropathic pain: The European Pain Federation (EFIC) classifies it in its 2018 position paper (European Journal of Pain) as third-line therapy, only after failure of first and second-line therapy, and only by clinicians with experience. This is a scientific society recommendation, not a regulatory authorisation.
• PTSD (post-traumatic stress disorder): No European agency has it as an authorised indication. Off-label prescription is possible in Germany and UK under medical judgement, but no official regulatory backing exists.
• Anorexia / weight loss in cancer and AIDS: Dronabinol has authorisation in the US (FDA, 1992) for this indication, but not in Europe.
• Anxiety and insomnia: Widely mentioned in public discussions. Without any European regulatory authorisation.

What the WHO says about cannabis in medicine

In January 2019, the WHO published its recommendations to the UN Secretary-General following the first complete critical review of cannabis by the Expert Committee (ECDD). The most relevant recommendation: remove cannabis from Schedule IV of the 1961 Convention — the most restrictive category, reserved for substances with no recognised medical use, where it was listed alongside heroin.

The UN Commission on Narcotic Drugs voted on 2 December 2020: 27 votes in favour, 25 against, 1 abstention. Approved by the minimum margin. Cannabis was removed from Schedule IV, recognising its therapeutic potential, but remains under full international control in Schedule I of the 1961 Convention. It was not any "global legalisation": it was a classification adjustment within the control system.

How to access medical cannabis in Spain in 2026

Spain now has three legal pathways for accessing medical cannabis, each with a different process:

1. Epidiolex for refractory epilepsy
   If the patient has Dravet syndrome, Lennox-Gastaut or tuberous sclerosis with epilepsy, Epidiolex is funded by the NHS. The process: consultation with a neurologist in a public or publicly-contracted private hospital → specialist prescription → dispensation in the hospital pharmacy of the same hospital. The copayment depends on the patient's income (NHS reference price system).
2. Sativex for spasticity due to multiple sclerosis
   Authorised since 2010, but without systematic NHS funding. The neurologist or specialist prescribes in hospital consultation. The cost (~€390 per vial) is borne by the patient unless there is an individual exception from the autonomous community. Some regions have occasional coverage agreements.
3. Standardised compounded formulas (RD 903/2025)
   Royal Decree 903/2025, in force since October 2025, allows the preparation of medical cannabis as a compounded formula in hospital pharmacy services. Only specialist doctors in hospitals can prescribe them. AEMPS manages the register of standardised preparations. Specific clinical indications and dosages were published in the National Formulary in early 2026. This is the newest access pathway and still in the actual implementation phase.

Can I travel in Europe with my cannabis medication?

Yes, but with a specific procedure that most patients are unaware of: the Schengen Certificate, provided for in Article 75 of the Convention Implementing the Schengen Agreement (CISA).

How the Schengen Certificate works

• Allows transporting up to 30 days' supply of a prescribed controlled substance across Schengen Area borders
• Issued by the competent health authority of the prescribing country, not directly by the doctor. In Spain: AEMPS. In Germany: BfArM
• Must specify: substance, dose, patient identity, trip duration
• Must be requested 6-8 weeks in advance
• Maximum validity: 30 days
• Austria requires an additional form for stays of more than 5 days

Directive 2011/24/EU on Cross-Border Healthcare obliges member states to recognise prescriptions issued in another state for authorised medicines. However, if the medicine (for example, German cannabis flowers) does not have marketing authorisation in the destination country, no pharmacy in that country is obliged to dispense it. The recognition of cannabis prescriptions is, in practice, theoretical for most patients.

The real barriers patients face in 2026

Legal frameworks exist. The problem is that the reality of access for the patient falls far short of what the headlines suggest.

In the UK, more than 40,000 specialists are legally eligible to prescribe medical cannabis. Only ~100 do so actively.

1. Shortage of prescribers. Medical stigma towards cannabis does not disappear by decree. A 2024 study (Sage Healthcare) documents significant knowledge gaps and safety concerns among specialist doctors in the UK. A 2025 study published in BMC Public Health on Germany — Europe's most permissive market — records measurable stigma even among medical cannabis users in the continent's most open framework.

2. Fragmented coverage. Less than 40% of European patients receive reimbursement for their medical cannabis treatment. In countries like Portugal (757 prescriptions throughout 2024), Italy (regional) or the UK (99% private), the law exists but access does not.

3. Supply shortages. In May 2025, police raids on licensed cultivation facilities in Portugal seized more than 25 tonnes of EU-GMP certified cannabis, causing disruptions in supply chains across Europe. Italian domestic production (SCFM) remains at ~300 kg/year for a country of ~60 million inhabitants.

4. Cost without insurance. In Germany without GKV: €50-150/month. In the UK privately: £200-500/month plus consultations. In the Netherlands: €200-400/month. For patients without coverage or in countries without reimbursement, the cost is prohibitive.

The European medical cannabis market in figures 2026

Germany is the most reliable market anchor. With 201 tonnes imported in 2025 at an average wholesale price of ~€5/g, the supply value to the German market exceeds €1 billion annually. This makes Germany, little more than a year after the MedCanG, the largest medical cannabis market in Europe — and possibly the world in terms of import volume.

The main sector players include Bedrocan Netherlands (the oldest producer with EU-GMP certification and presence in multiple European countries), Demecan (first company with a cultivation licence in Germany, July 2024), Aurora Cannabis (with a facility in Leuna, Germany, and its IndiMed brand launched in January 2025), and Sanity Group (acquired by Organigram Global in February 2026).

Frequently asked questions

Conclusion

Medical cannabis in Europe in 2026 is a rapidly evolving sector but with a clear fracture between what the laws say and what a real patient experiences. Germany has created in less than two years the world's largest medical access market. The Czech Republic offers the most generous reimbursement. Spain, with RD 903/2025, has taken its first real step.

But in countries like Portugal, Italy or the UK, legal frameworks coexist with minimal effective access due to supply, insurance coverage or willing prescribers.

What is clear: the only two medicines with central European approval — Epidyolex for refractory epilepsy and Sativex for MS spasticity — have very specific indications. Medical cannabis is not a broad-spectrum therapy with regulatory approval. It is an expanding field, with growing evidence in some indications, requiring specialised medical care and up-to-date knowledge of each country's legal framework.